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1 Introduction
Administration of glucocorticoids to women at
risk of preterm delivery for the prevention of
neonatal respiratory distress syndrome (RDS) has
become a routine treatment in many obstetrical
centers. In the quest for more efficient methods
to accelerate lung maturation in the fetus a num-
ber of compounds have been investigated in exper-
imental animals [2]. Thyroid hormones [1, 12, 33,
44], bromhexine metabolite VIII (ambroxol) [41,
48], carnitine [40] and thyrotropin stimulating hor-
mone (TRH, LIGGINS unpublished) have recently
also been used in humans.
In this paper we will review the effects on lung
maturation of glucocorticoids and report recent
relevant findings from our laboratory.
2 Glucocorticoids
2.1 Experimental data
Experiments in vitro and in vivo in several species
including humans have shown that glucocorti-
coids stimulate the synthesis and secretion of pul-
monary surfactant, promote morphological devel-
opment of the lung and enhance survival of pre-
maturely born fetuses [13, 15, 18, 22, 23, 34].
Glucocorticoid receptors have been demonstrated
in lung tissue and in cultures enriched in adult or
fetal alveolar type II cells [7, 16]. A number of
direct and indirect mechanisms of glucocorticoid
action has been proposed:
1 — Increase in surfactant synthesis through en-
zyme induction [38],
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3 — Induction of pulmonary ß-adrenergic recep-
tors [9, 31],
4— Stimulation of production of fibroblast —
pneumonocyte factor [14, 37],
5 — Increase in plasma levels of triiodothyronine
(in part through 6) [47],
6 — Conversion of thyroxine to triiodothyronine
[47],
7 — Induction of conversion of noradrenaline to
adrenaline [32],
8— Stimulation of glycogenolysis [17].
Lung maturation at term fails to occur in sheep
hypophysectomized at 110 days gestation [26].
While infusion of ACTH at term increases disten-
sibility and stability of the lungs in hypophysec-
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tomized fetuses, infusion of cortisol is ineffective
[26]. Conversely, infusion of ACTH at term to
fetal sheep adrenalectomized at 100 days gestation
fails to accelerate lung maturation whereas infu-
sion of cortisol increases distensibility of the lung
although stability of the lung and alveolar surfac-
tant levels are not increased [27]. This suggests
that cortisol and at least one other factor are
required for lung maturation in sheep and that
structural changes (rather than surfactant alone)
contribute to changes in distensibility.
2.2 Clincial data
Although it is well established that antenatal glu-
cocorticoid treatment reduces the incidence and
severity of RDS in prematurely born infants it is
also evident that a significant number of fetuses
do not respond to the treatment [4, 8, 10, 21, 25,
35, 45, 50]. This is of particular consequence in
very immature fetuses which have been found by
some authors not to respond to glucocorticoids
[4, 10, 50]. In the Auckland trial, the incidence of
RDS was lower in treated males of less than 30
weeks gestation than in controls (21% versus
61%, p < 0.015) but not in females [20]. The study
of BALLARD et al suggested that the incidence of
RDS is significantly reduced by betamethasone
treatment in infants of about 27 to 30 weeks of
gestation (birth weight between 751 g and 1250 g),
but that smaller and larger infants do not benefit
from the treatment [4]. In a retrospective con-
trolled study on 678 infants with a mean
birthweight of 1100 g and a mean gestational age
of 28.5 weeks, perinatal mortality was nearly
halved and body weight and head circumference
were greater at two years of age in treated infants
than in controls [11].
When 24 mg of betamethasone is administered
intramuscularly either in two divided doses 12 h
apart or in four divided doses 12 hourly, levels of
fetal glucocorticoid activity are in the range of
those in newborns with RDS or with prolonged
premature rupture of the membranes [5, 6]. It is
therefore unlikely that these regimens produce
teratogenic effects [3, 5]. Extensive physical, psy-
cho-motor, general medical, neurological, pul-
monary and immunological testing of infants
treated antenatally with glucocorticoids have con-
firmed that child development is unlikely to be
affected by antenatal glucocorticoid prophylaxis
[20, 24, 29, 30, 49].
3 Synergistic hormonal effects
3.1 Experiments in fetal sheep
In fetal sheep, infusion of cortisol at around 125
days gestation (term is 147 days) produces only a
small increase in pulmonary distensibility [43] or
has no detectable effect on lung maturation [28].
Although combined infusion of cortisol + trii-
odothyronine or cortisol + adrenaline or cortisol
+ triiodothyronine + prolactin increase alveolar
surfactant, only a combination of cortisol + trii-
odothyronine + prolactin increases distensibility
of the lung above values obtained with infusion
of cortisol alone [43]. This suggests that
— there is synergism on alveolar surfactant pro-
duction between cortisol and triiodothyronine
and between cortisol and adrenaline,
— there is synergism between cortisol, triiodothy-
ronine and prolactin in increasing distensibility
of the lung, and
— distensibility of the lung does not depend on
surfactant levels alone.
Elastin and collagen concentration were higher in
lungs that were distensible and stable after hor-
mone infusion than in non-distensible and un-
stable lungs, suggesting that changes in connective
tissue are associated with changes in the mechani-
cal properties of the fetal lung [42].
Similar results were obtained in fetal sheep infused
with TRH between Days 121 and 128 of gestation.
Infusion of TRH, which increases ovine fetal
plasma levels of triiodothyronine and prolactin
[46], does not increase distensibility and stability
of the ovine fetal lung, whereas combined infusion
of TRH + cortisol produces distensible and stable
lungs [28].
3.1 Possible clinical applications
In humans, TRH crosses the placenta and produ-
ces a rise in fetal plasma triiodothyronine [39]. As
in sheep, there appears to be refractoriness of
the human lung to glucocorticoids at an early
gestational age [4, 10, 20, 50]. Given the excellent
response of the sheep fetus to combined treatment
with TRH and cortisol at a gestational age when
the response to cortisol alone is negligible [28],
administration of TRH + betamethasone to
women at risk of very premature birth may be
more efficient than treatment with betamethasone
alone. The validity of this speculation is currently
being tested in our institution by a controlled,
double-blind clinical trial.
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4 Conclusion
Although the efficacy of antenatal glucocorticoid
therapy for the propylaxis of RDS is well estab-
lished it is also true that many fetuses, particularly
of low gestational age, do not respond to the
treatment. Multihormonal treatment accelerates
lung maturation in sheep at an early gestational
age when infusion of cortisol alone is ineffective.
It remains to be seen whether such therapy is
effective in the human fetus.
Summary
The paper reviews the effects on lung maturation of
glucocorticoids in animals and humans and presents
relevant recent findings from the author's laboratory. It
is now well established that antenatal glucocorticoid
treatment reduces the incidence and severity of the res-
piratory distress syndrome (RDS) in prematurely born
infants. The recommended doses of glucocorticoids pro-
duce fetal glucocorticoid activity levels similar to those
of newborns with RDS or prolonged rupture of the
membranes. Extensive follow-up studies have shown
that adverse effects on child development are unlikely
to occur. It is also evident that a significant number of
fetuses do not respond to the treatment, which is of
particular consequence in fetuses of less than 28 weeks
gestation. These fetuses are less likely to respond to
glucocorticoid therapy than fetuses between 28 and 32
weeks gestation and are at a higher risk of developing
complications due to their immaturity. In fetal sheep,
there is a similar decrease in the efficacy of glucocorti-
coids on lung maturation with decreasing gestational
age. Simultaneous infusion of cortisol, triiodothyronine
and prolactin but not of any of these hormones adminis-
tered singly or in combination of two produced mature
lungs in fetal sheep of 125 days gestation. Similar results
were obtained with thyrotropin releasing hormone
(TRH) and cortisol. It remains to be seen whether the
combined administration of glucocorticoids and TRH
accelerates lung maturation in human fetuses.
Keywords: Fetal organ maturity, follow-up studies, glucocorticoids, lung, prolactin, respiratory distress syndrome-
prevention, sheep, thyrotropin releasing hormone, triiodothyronine.
Zusammenfassung
Neue Möglichkeiten zur hormonellen Induktion der feta-
len Lungenreifung
Die vorliegende Arbeit liefert eine Übersicht zum Thema
der Beeinflussung der Lungenreifung durch Glukokorti-
koide bei Menschen und Tieren. Darüber hinaus werden
neuere Ergebnisse aus Versuchsreihen, die von den Auto-
ren durchgeführt werden, mitgeteilt. Es gilt als gesichert,
daß eine antenatale Glukokortikoidbehandlung die Inzi-
denz und den Schweregrad eines Atemnotsyndroms
(RDS) bei Frühgeborenen reduziert. Die empfohlene
Glukokortikoiddosis erzeugt eine Kortikoidaktivität
beim Feten, wie sie auch bei Neugeborenen mit RDS
oder nach vorzeitigem Blasensprung gefunden wird.
Ausgedehnte Nachuntersuchungen haben gezeigt, daß
unerwünschte Effekte bei der kindlichen Entwicklung
sehr unwahrscheinlich sind. Offensichtlich spricht aber
eine beträchtliche Anzahl von Feten nicht auf die Be-
handlung an. Dies ist besonders bedeutungsvoll für Fe-
ten unterhalb der 28. Schwangerschaftswoche, da diese
in geringerem Maße auf die Kortikoidtherapie anspre-
chen als Feten zwischen der 28. und 32. Woche und eher
in Schwierigkeiten geraten infolge ihrer Unreife. Beim
Schaffeten sind die Glukokortikoide ebenfalls mit ab-
nehmendem Gestationsalter weniger wirksam. Die
gleichzeitige Infusion von Kortisol, Trijodthyronin und
Prolaktin führte zu reifen Lungen bei Schaffeten mit
125 Tagen Gestationsdauer. Dies gilt nicht, wenn die
Substanzen einzeln oder als Zweierkombination verab-
reicht wurden. Bei Verwendung von Thyrotropin-Rele-
asing-Hormon (TRH) und Kortisol wurden vergleich-
bare Ergebnisse erzielt. Es bleibt nachzuweisen, ob auch
bei menschlichen Feten die kombinierte Gabe von TRH
und Glukokortikoiden die Lungenreifung beschleunigt.
Schlüsselwörter: Fetale Organreifung, Nachuntersuchungen, Glukokortikoide, Lunge, Prävention eines RDS,
Prolaktin, Schaf, Thyrotropin-Releasing-Hormon, Trijodthyronin.
Resume
Nouvelles approches concernant Pacceleration hormonale
de la maturation pulonaire fcetale
Get article passe en revue les effets sur la maturation
pulmonaire des glucocortico'ides chez animal et chez
Fhomme et presente des donnees recentes sur le sujet
provenant du laboratoire des auteurs. II est bien etabli
que le traitement par glucocortico'ides antenatal diminue
l'incidence et la severite du syndrome de detresse respira-
toire (SDR) chez les enfants nes prematurement. Les
doses recommandees de glucocortico'ides produisent des
J. Perinat. Med. 15(1987)
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taux plasmatiques d'activite glucocortico'ide semblables
aux taux mesures chez les nouveaux-nes atteints de SDR
et d'enfants nes apres rupture prolongee des membranes.
Des etudes de controle ont demontre qu'il est peu proba-
ble que le traitement ait des effets secondaires sur le
developpement de l'enfant. II est aussi vrai que cette
therapie est inefficace dans un bon nombre de cas. Ceci
est d'une importance capitale chez le foetus de moins de
28 semaines de gestation. Celui-ci est particulierement
dispose a des complications dues ä Pimmaturite et re-
pond moins bien aux glucocortico'ides que le foetus entre
28 and 32 semaines. Chez le foetus du mouton 1'effet
des glucocortico'ides sur la maturation pulmonaire dimi-
nue de fa$on semblable avec un äge de gestation decrois-
sant. Des perfusions de cortisol, de triiodothyronine et
de prolactine administrees simultanement produisent des
poumons matures dans le foetus de mouton de 125 jours
de gestation; cela ne se produit pas si une seule de
ces hormones est administree ou si deux d'entre elles
seulement sont combinees. Des resultats similaires ont
ete obtenus avec de la thyrotropin releasing hormone
(TRH) et du cortisol. II reste a voir si administration
combinee de glucocortico'ides et de TRH accelere la
maturation pulmonaire chez les foetus humains.
Mots-cles: Etudes de surveillance, glucocortico'ides, maturite des organes foetaux, mouton, poumon, prolactine,
syndrome de detresse respiratoire-prevention, thyrotropin releasing hormone, triiodothyronine.
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